CS
PBYI icon

Candriam SCA’s Puma Biotechnology PBYI Stock Holding History

Candriam SCA’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Hold
0
– – – 784
2020
Q2 		– Sell
-82,200
Closed -$703K – 849
2020
Q1 		$703K Hold
82,200
– – 0.01% 686
2019
Q4 		$719K Sell
82,200
-141,000
-63% -$1.17M 0.01% 703
2019
Q3 		$2.4M Hold
223,200
– – 0.03% 457
2019
Q2 		$2.82M Buy
223,200
+208,586
+1,427% +$4.8M 0.04% 441
2019
Q1 		$567K Sell
14,614
-331,123
-96% -$10.1M 0.01% 698
2018
Q4 		$7.04M Buy
345,737
+29,537
+9% +$886K 0.11% 219
2018
Q3 		$14.5M Buy
316,200
+211,200
+201% +$10.2M 0.19% 124
2018
Q2 		$6.21M Buy
105,000
+37,000
+54% +$2.14M 0.1% 258
2018
Q1 		$4.63M Buy
68,000
+27,000
+66% +$2.02M 0.08% 294
2017
Q4 		$4.05M Sell
41,000
-16,500
-29% -$1.85M 0.07% 310
2017
Q3 		$6.89M Buy
57,500
+8,500
+17% +$791K 0.12% 212
2017
Q2 		$4.28M Sell
49,000
-105,500
-68% -$5.9M 0.08% 293
2017
Q1 		$5.75M Buy
154,500
+45,000
+41% +$1.64M 0.11% 221
2016
Q4 		$3.36M Buy
109,500
+41,500
+61% +$1.79M 0.08% 278
2016
Q3 		$4.56M Sell
68,000
-24,000
-26% -$1.21M 0.11% 208
2016
Q2 		$2.74M Sell
92,000
-17,000
-16% -$531K 0.07% 264
2016
Q1 		$3.18M Buy
109,000
+24,700
+29% +$1.12M 0.08% 258
2015
Q4 		$6.61M Buy
84,300
+24,000
+40% +$1.88M 0.18% 141
2015
Q3 		$4.54M Buy
60,300
+31,300
+108% +$2.96M 0.11% 218
2015
Q2 		$3.39M Buy
29,000
+12,000
+71% +$2.17M 0.07% 292
2015
Q1 		$4.01M Buy
17,000
+3,000
+21% +$641K 0.08% 288
2014
Q4 		$2.65M Buy
+14,000
New +$3.11M 0.06% 323

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Candriam SCA's PBYI Position: Q3 2021 in Review

Candriam SCA held its Puma Biotechnology (PBYI) position steady in Q3 2021 at 0 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #784.

Candriam SCA first reported a position in PBYI in Q4 2014 and has held it in 22 quarters since. The position peaked at $14.5M in Q3 2018. 115 funds tracked by Wall St. Rank hold PBYI as of Q3 2021.

  • Candriam SCA held 0 shares of Puma Biotechnology worth $502K as of Q3 2021.
  • Candriam SCA left its Puma Biotechnology share count unchanged in Q3 2021.
  • Puma Biotechnology made up ﹤0.01% of Candriam SCA's portfolio in Q3 2021, its #784 holding.
  • Candriam SCA first reported a position in Puma Biotechnology in Q4 2014 and has held it in 22 quarters since.
  • Candriam SCA's Puma Biotechnology position peaked at $14.5M in Q3 2018.
  • 115 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.